MeiraGTx Holdings PLC
MGTXHealthcare|Biotechnology|USA
$13.38
-0.56 (-3.98%)
Clinical Trials (16)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05926765 A Study of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late Xerostomia | Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Parotid Glands | P2 | Recruiting | 276 | RCT, Double-blind | — |
| NCT05894343 Long-term Follow-up of Glutamic Acid Decarboxylase (GAD) Gene Transfer in Parkinson's Disease | Parkinson's Disease | P1P2 | Active | 13 | RCT, Open-label | — |
| NCT02446249 Safety of a Single Administration of AAV2hAQP1, an Adeno-Associated Viral Vector Encoding Human Aquaporin-1 to One Parotid Salivary Gland in People With Irradiation-Induced Parotid Salivary Hypofunction | Squamous Cell Head and Neck Cancer, Radiation Induced Xerostomia | P1 | Active | 17 | Open-label | AAV2hAQP1 |
| NCT05060341 Long-Term Follow-Up Study of AAV2hAQP1 for Radiation Induced Xerostomia | Radiation-induced Xerostomia | Active | 22 | — | — | |
| NCT05603312 A Double-blind Study to Evaluate the Safety of Glutamic Acid Decarboxylase Gene Transfer in Parkinson's Participants | Parkinson's Disease | P1P2 | Completed | 14 | RCT, Double-blind | — |
| NCT02781480 Clinical Trial of Gene Therapy for the Treatment of Leber Congenital Amaurosis (LCA) | Leber Congenital Amaurosis | P1P2 | Completed | 15 | Open-label | AAV RPE65 |
| NCT03001310 Gene Therapy for Achromatopsia (CNGB3) | Achromatopsia | P1P2 | Completed | 23 | Open-label | AAV - CNGB3 |
| NCT06544798 Long-term Follow-up of Gene Therapy for Radiation-Induced Xerostomia | Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Parotid Glands | P2 | By Invite | 276 | RCT, Open-label | — |
| NCT03252847 Gene Therapy for X-linked Retinitis Pigmentosa (XLRP) - Retinitis Pigmentosa GTPase Regulator (RPGR) | X-Linked Retinitis Pigmentosa | P1P2 | Completed | 49 | RCT, Open-label | — |
| NCT03758404 Gene Therapy for Achromatopsia (CNGA3) | Achromatopsia | P1P2 | Completed | 11 | Open-label | adeno-associated virus vector AAV- CNGA3 |
| NCT04043104 A Phase 1 Open-Label, Dose Escalation Study to Determine the Optimal Dose, Safety, and Activity of AAV2hAQP1 in Subjects With Radiation-Induced Parotid Gland Hypofunction and Xerostomia | Radiation-Induced Parotid Gland Hypofunction, Xerostomia Due to Radiotherapy | P1 | Completed | 24 | Open-label | AAV2hAQP1: 1 x 10^11 vg/gland (single gland), AAV2hAQP1: 3 x 10^10 vg/gland (both glands), AAV2hAQP1: 3 x 10^11 vg/gland (single gland), AAV2hAQP1: 1 x 10^11 vg/gland (both glands), AAV2hAQP1: 1 x 10^12 vg/gland (single gland), AAV2hAQP1: 3 x 10^11 vg/gland (both glands), AAV2hAQP1: 3 x 10^12 vg/gland (single gland), AAV2hAQP1: 1 x 10^12 vg/gland (both glands) |
| NCT03349242 Natural History Study of Patients With X-linked Retinal Dystrophy Associated With Mutations in Retinitis Pigmentosa GTPase Regulator (RPGR) | Retinitis Pigmentosa | Completed | 140 | — | — | |
| NCT03278873 Long-Term Follow-Up Gene Therapy Study for Achromatopsia CNGB3 and CNGA3 | Achromatopsia | Terminated | 34 | — | Prior exposure to AAV-CNGA3 or AAV-CNGB3 | |
| NCT02714816 Natural History Study of Patients With Leber Congenital Amaurosis Associated With Mutations in RPE65 | Leber Congenital Amaurosis | Completed | 37 | — | — | |
| NCT02946879 Long-Term Follow-Up Gene Therapy Study for Leber Congenital Amaurosis OPTIRPE65 (Retinal Dystrophy Associated With Defects in RPE65) | Leber Congenital Amaurosis (LCA), Eye Diseases | Completed | 15 | — | AAV OPTIRPE65 | |
| NCT04124185 Natural History Study for Achromatopsia | Achromatopsia | Completed | 85 | — | — |